Board of Directors

Mr. Luke Beshar

Mr. Beshar has more than 35 years of financial and executive leadership experience and has served as a director since December 2015 and as the Executive Chairman of our board of directors since December 2016. Previously, Mr. Beshar served as Chief Financial Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since November 2007 and January 2012, respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc. Prior to that he served in several managerial positions with NPS Pharmaceuticals, Netexit, Inc. Camberx Corporation, Cegedim Inc., Expanets, Inc., PNY Technologies, Inc., Dendrite International, WSR Corporation, the Genlyte Group, Inc. and Bairnco Corporation. Mr. Beshar has been an independent director of Trillium Therapeutics Inc. (NASDAQ: TRIL), since March 2014 and Regenxbio Inc. (NASDAQ: RGNX) since April 2015. He is a Member of the New York Society of Certified Public Accountants. He has a B.A. in Accounting and Finance from Michigan State University and is a graduate of the Executive Program of the Darden Graduate Business School at the University of Virginia.

 

 

Dr. Roger Garceau

Dr. Garceau has more than 30 years of broad pharmaceutical industry experience and has served as a director since March 2016 and as our Chief Development Advisor since December 2016. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc. Previously, Dr. Garceau has also served in several managerial positions with NPS Pharmaceuticals, Inc., Sanofi-aventis and Pharmacia Corporation. Dr Garceau has been a non-executive director of Enterome SA since December 2016. He is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.

Mr. Zeev Bronfeld

Mr. Bronfeld has served as a member of our board of directors since 2010 and as chairman of our board of directors since September 2014 and until November 2016. Mr. Bronfeld has vast experience in the management and value building of biotechnology companies. From 2010 through July 2014, he served as the chairman of the board of Protalix BioTherapeutics, Inc. (NYSE: PLX) and has been a director on its board since 2006. Mr. Bronfeld serves as chairman of the board of directors of D.N.A Biomedical Solutions Ltd. Mr. Bronfeld is also a director of several privately-held companies, including The Trendlines Group Ltd, Contipi Medical Ltd. and as chairman of the board of TransBiodiesel Ltd. Mr. Bronfeld holds a B.A in Economics from the Hebrew University of Jerusalem.

Mr. David Ben Ami

Mr. Ben Ami has served as a member of the Board of Directors since 2014. Mr. Ben-Ami has more than 25 years of experience with activities in management, business development and corporate strategy in the life sciences industry. He served as chief executive officer of NVR Labs from 2005 to 2010, country director of Boston Scientific, Israel from 2003 to 2005, and director of business development of Teva Israel from 1999 to 2003. In 2008, he co-founded Macrocure. Mr. Ben-Ami currently serves as a director of the board of directors of Macrocure and was the chairman of its board. Mr. Ben Ami is the Managing partner of Corundum Open Innovation and also sits on the board of directors of Degania Silicone Ltd. He received his M.B.A. and B.A. in Economics & Management from Tel-Aviv University.

Mr. Chaim Davis

Mr. Davis has served as a member of the Board of Directors since 2013. Mr. Davis is the managing member of the Revach Fund L.P., a sector-specific lifescience fund focusing on micro to mid-cap companies, which he founded in 2005. He has also served as a consultant to other hedge funds including Gem Partners, KOM Capital Management and Maot Group. From 2010 to 2014, he served as a director of AtheroNova Inc. (OTCBQ: AHRO), and from 2001 to 2004, he served as a healthcare analyst at The Garnet Group. Mr. Davis received his B.A. from Columbia University.

Mr. Gerald Lieberman

Mr. Lieberman has served as a member of the Board of Directors since 2014. From 2000 until 2009, Mr. Lieberman was an executive at AllianceBernstein L.P. There, he was elected chief operating officer and a director in November 2003 and added the title of president in November 2004. Prior to that, Mr. Lieberman was senior vice president for finance and administration at Sanford C. Bernstein & Co., Inc. He has also held senior roles at Fidelity Investments and Citicorp. Mr. Lieberman currently serves on the board of Teva Pharmaceutical Industries Ltd. and serves as a special advisor at Reverence Capital Partners, a private investment firm focused on the middle-market financial services industry. Mr. Lieberman earned a B.S. from the University of Connecticut and attended New York University’s Graduate School of Business Administration. He is a certified public accountant, and a trustee of the University of Connecticut Foundation, Inc., where he is chairman of the finance committee and a member of the investment and executive committees.

Mr. Yonatan Malca

Mr. Malca has served as a member of the Board of Directors since 2011. Mr. Malca currently serves as a CEO and Director of D.N.A Biomedical Solutions Ltd., one of our principal shareholders, a position he has held since 2010. Mr. Malca also serves as a director of Arko Holdings Ltd., an Israeli public company. Mr. Malca also serves on the board of directors of a number of private companies, including as chairman of the board of directors of Cardioart Technologies LTD, a medical device company. Mr. Malca received a B.A. and an M.A. from Bar Ilan University.

Dr. Phillip Schwartz

Dr. Schwartz has more than twenty years of biotech and pharmaceutical industry experience. He has served as CEO and director of the board of director of Entera since its inception in September 2010. Previously he has held multiple positions in medical affairs, business development and clinical trial development at Serono and was served as manager of clinical affairs at Endo Pharmaceuticals. He has also consulted privately for more than 20 large biotech and pharmaceutical companies and a number of venture capital firms. Dr Schwartz has multiple publications in tier one peer reviewed journals and has presented papers at numerous international conferences. Dr. Schwartz completed his BA in psychology and architecture at Columbia University. He then studied and worked in neurobiology with Nobel Laureate Professor Torsten Wiesel of the Rockefeller University. After completing his project, Dr. Schwartz studied immunology with Professor Irun Cohen at the Weizmann Institute, receiving his MSc. in 1991. In 1997 Dr. Schwartz received his Ph.D. in neurobiology/development/oncology from Harvard Medical School.